The workshop will provide a window into the wonderful world of toxicologic pathology. In a broad sense, toxicologic pathology encompasses basic medical research, and the toxicology and pathology involved in safety assessment of regulated products in general commerce. These include agents with potential for toxicity from environmental exposures (chemicals, food, radiation, noise) as well as of therapeutic candidates (small molecule drugs, biologics, medical devices, all other agents) being developed for the diagnosis, prevention and treatment of diseases, including bioassays (in-vivo screening methods and animal models of disease) to fulfill the primary objectives of safety within the realm of regulatory risk assessment. The session includes presentations on selected topics ending with an open platform discussion between the audience and speakers.

Welcome – Jerry Ward

Introduction to Toxicologic Pathology - Deepa Rao, Greenfield Pathology Services, Inc.

Toxicologic Pathology Nomenclature & Diagnosis – Jerry Ward, Global VetPath

Environmental Toxicologic Pathology – Ann Hubbs, NIOSH, CDC

Safety Assessment – Emily Meseck, Novartis
Brief Break

The Role of the Pathologist in Drug Development: Focus on Emerging Technologies – Keith Mansfield, Novartis

Stem cell therapy development – Kevin Keane, Blueprint Medicines

The case of platform-related toxicologic pathology of AAV-based gene therapy products – Basel Assaf, Sanofi

Workshop Summary and Roundtable Discussion - Ingrid Pardo, Biogen